Arno's AR-12 antimicrobial drug data shows positive results
The antimicrobial acts as a broad-spectrum drug candidate. Stefan Prontiuk, chief development officer of the company, presented preliminary data of the drug's success in inhibiting replication of the chikungunya virus during his podium presentation.
“Prior AR-12 antiviral investigations demonstrate potent activity across a wide range of distinct pathogenic viruses such as Influenza A, Epstein Barr virus, and hemorrhagic fever viruses including Ebola, Marburg, Nipah, Lasa, Junin, and Yellow fever,” Proniuk said. “In the two studies we presented at ICAAC/ICC, we now show that AR-12 has a first-in-class, novel mechanism of action that enables its potential for broad-spectrum antimicrobial activity, providing additional rationale for the continued development of the compound against a number of infectious disease targets.”
European officials have granted this candidate two orphan drug designations for the treatment of tularemia and cryptococcosis. Its potential against analogues to the Ebola virus and other pathogens has also garnered biodefense related interest from the U.S. Army Medical Research Institute of Infectious Diseases.
The AR-12 is also being studied for its potential as an antifungal treatment and has shown activity against several fungal infections.